Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.78 USD

5.78
34,571

-0.05 (-0.86%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457

Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.

Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study

Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.

Kamada (KMDA) Gains But Lags Market: What You Should Know

In the latest trading session, Kamada (KMDA) closed at $5.76, marking a +0.17% move from the previous day.

Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down

Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.

Seattle Genetics Closes Enrollment in Cervical Cancer Study

Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

4 Small Biotech Stocks Likely to Witness More Upside in 2019

The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

Kamada (KMDA) Flat As Market Gains: What You Should Know

Kamada (KMDA) closed at $5.79 in the latest trading session, marking no change from the prior day.

Blueprint Medicines Expediates Filings for Key Candidates

Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.

Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, SYNNEX and Walker & Dunlop

Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, SYNNEX and Walker & Dunlop

Agios (AGIO) Surges More Than 40% Year to Date: Here's Why

Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.

Agios Gains Breakthrough Therapy Status for Tibsovo Combo

Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.

Zacks.com featured expert Kevin Matras highlights: Kamada, Herc, Medifast, SkyWest and SP Plus

Zacks.com featured expert Kevin Matras highlights: Kamada, Herc, Medifast, SkyWest and SP Plus

Bet on These 5 Stocks With Rising Cash Flows for Higher Gains

Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health.

Best 6 Bets With Sound Net Profit Margin to Lift Portfolio

Let's take a look at six excellent stocks with handsome net profit margin that can build a winning portfolio.

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop

Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, Middlefield and Walker & Dunlop

Scoop Up Big Gains With 5 Stocks Enjoying Rising Cash Flows

Cash is the lifeblood of any business. It offers strength, vitality and flexibility to make investment decisions, and the fuel to run the growth engine.

Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4

Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.